Lagophthalmos successfully treated by high pretarsal placement

Article

Gold weights inserted using a high pretarsal placement can treat lagophthalmos.

Gold weights inserted using a high pretarsal placement can treat lagophthalmos, discovered a study in the British Journal of Ophthalmology.

A retrospective review, conducted by Dr Raman Malhotra and his team, Corneo Plastic Unit, Queen Victoria Hospital NHS Trust, East Grinstead, Sussex, UK, included 107 consecutive gold weight implants in 95 lagophthalmos patients studied over a 5 year period.

Gold weights were implanted using a combination of high pretarsal placement, levator recession and fixation. Revision surgery for the gold implants included repositioning, removing or exchanging the implants.

Photographs of each case were taken preoperatively and 6 months postoperatively in order to conduct a blind assessment of eyelid parameters.

Of the patients studied, five eyes needed three further revisions each. The indications for these revisions included 15 eyelids prominent implants, poor eyelid contour in 14 eyelids, extrusion in two eyelids and persistent erythema in eight eyelids. The revisions included six platinum chain exchanges, three replacements, eight repositioned implants and four removals.

Revision procedures were mostly completed within 12 months, with a complication rate of 1 in 6. The most frequent indications for revisions were unsatisfactory cosmesis from prominence of implant and poor eyelid contour.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.